Jason Mouabbi, MD, is an assistant professor in the Department of Breast Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
A panelist discusses how the landmark EMERALD study established elacestrant as an effective treatment for heavily pretreated patients with ESR1 mutations, showing 8 to 9 months median progression-free survival versus less than 2 months with standard care.
A panelist discusses how the SERENA-6 study presented at ASCO 2025 showed that switching therapy early based on molecular progression (ESR1 mutation emergence) before radiological progression improved outcomes, with a 60% reduction in risk.
A panelist discusses how testing for ESR1 mutations should be performed after every progression using liquid biopsies and how elacestrant is currently the only approved oral SERD that effectively targets these mutations.
Jason A. Mouabbi, MD, discusses how ESR1 mutations can cause patients with HR-positive, HER2-negative breast cancer to develop endocrine resistance.
Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma
Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.
Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer.
